Full Papers
Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: a multi-state Markov model analysis
J. Fournier1, B. Boussat2, B. Dervaux3, P. Gaudin4, X. Romand5
- Department of Epidemiology and Medical Evaluation, CHU Grenoble Alpes, Grenoble, France. jfournier@chu-grenoble.fr
- Department of Epidemiology and Medical Evaluation, CHU Grenoble Alpes, Grenoble, and Laboratory TIMC, UMR 5525, CNRS, Joseph Fourier University, Grenoble, France.
- Department of Research and Innovation, CHRU Lille, Lille, France.
- T-RAIG, TIMC, UMR 5525 CNRS, University of Grenoble Alpes, CHU Grenoble Alpes, Grenoble, and Department of Rheumatology, CHU Grenoble Alpes, Grenoble, France.
- T-RAIG, TIMC, UMR 5525 CNRS, University of Grenoble Alpes, CHU Grenoble Alpes, Grenoble, and Department of Rheumatology, CHU Grenoble Alpes, Grenoble, France.
CER17847
2025 Vol.43, N°1
PI 0062, PF 0069
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 39360378 [PubMed]
Received: 15/05/2024
Accepted : 15/07/2024
In Press: 03/10/2024
Published: 23/01/2025
Abstract
OBJECTIVES:
This study aimed to evaluate the cost-effectiveness of introducing tofacitinib in second-line therapies after methotrexate failure for rheumatoid arthritis in France.
METHODS:
Using a Markov model, we simulated a cohort of 10,000 patients based on literature data to compare various treatment strategies. The reference strategy included the four classes of biologics commonly used in France (TNFi, tocilizumab, abatacept, rituximab). The trial strategies additionally included tofacitinib at different introduction positions. The cycle duration was set at 6 months, and the time horizon was a lifetime. The data for severe adverse effects were sourced from the ORAL Surveillance study.
RESULTS:
Compared to the reference strategy, introducing tofacitinib is a dominant strategy, regardless of its introduction position. Introducing it as the first-line treatment results in the greatest cost savings (€1,679 per patient) while increasing quality-adjusted life years (QALYs) by 0.29. According to the one-way sensitivity analysis, the discount rate and the cost of TNFi were the two variables that most influenced costs, while the change in HAQ score and the discount rate were the two variables that most influenced QALYs.
CONCLUSIONS:
Our study represents the first assessment of the cost-effectiveness of tofacitinib in France and incorporates the latest adverse effects reported in the literature. It reinforces previously obtained results from other countries. Our study has some limitations, mainly related to the use of data from clinical trials. Our analysis is limited to severe adverse effects, and their cost is extrapolated from the average hospitalisation cost. The estimated costs are therefore underestimated for chronic diseases such as cancer.
